The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer
| Autor: | Satoshi Koyama, Kazunori Fujiwara, Kenkichiro Taira, Hiromi Takeuchi, Takahiro Fukuhara |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Side effect Colorectal cancer medicine.medical_treatment Placebo chemotherapy Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Mucositis Gargling Chemotherapy gargling business.industry Head and neck cancer Induction chemotherapy General Medicine medicine.disease Hangeshashinto 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Original Article head and neck cancer business oral mucositis |
| Zdroj: | Taira Kenkichiro, Fujiwara Kazunori, Fukuhara Takahiro et al. The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer. Yonago Acta Medica. 2020, 63(3). 183-187. doi: 10.33160/yam.2020.08.007. Yonago Acta Med |
| ISSN: | 0513-5710 |
| DOI: | 10.33160/yam.2020.08.007. |
| Popis: | [Background] Oral mucositis (OM) is a side effect of chemotherapy in head and neck cancer. Severe OM often has a large impact on quality of life. Therefore, the treatment of OM during chemotherapy is very important. It was recently reported that Hangeshashinto (TJ-14), a Japanese traditional medicine (Kampo), is effective for OM caused by fluorinated pyrimidinebased agents used in colon cancer. We investigated the efficacy of TJ-14 for OM. [Methods] We enrolled patients with head and neck cancer who were treated with induction chemotherapy between September 2014 and March 2016. In this double-blind trial, patients were randomly assigned to the TJ-14 group or placebo group. Patients were instructed to dissolve 2.5 g of TJ-14 or placebo in 100 ml of drinking water, rinse their mouths with the solution for 30 s and then spit it out. They were not allowed to eat anything for 30 minutes before or after using the mouthwash. [Results] The incidence of ≥ grade 2 OM was 37.5% (three patients) in the TJ-14 group and 50.0% (four patients) in the placebo group, with no significant difference between the two groups. The mean day of onset was 9.7 in the TJ-14 group and 6.7 in the placebo group. The mean duration of ≥ grade 2 OM was 1.3 days in the TJ-14 group and 3.7 days in the placebo group. Thus TJ-14 significantly reduced the duration of ≥ grade 2 OM. [Conclusion] Treatment of OM with TJ-14 was associated with a statistically significant reduction in the duration of ≥ grade 2 OM compared to placebo. Gargling with TJ-14 is a safe and effective method of administering the drug to patients with head and neck cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|